Chronic lymphocytic leukaemia

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 605-615

  Boelens, Jerina ^a   Lust, Sofie ^a   Vanhoecke, Barbara ^a   Offner, Fritz ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

B cell receptor; Chronic lymphocytic leukaemia; Prognostic factors; Review

Indexed keywords

B LYMPHOCYTE RECEPTOR; CELL MARKER; DNA; MOLECULAR MARKER; PROTEIN KINASE ZAP 70; SURROGATE IMMUNOGLOBULIN LIGHT CHAIN;

CANCER CLASSIFICATION; CANCER INCIDENCE; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IGVH GENE; IMMUNOGLOBULIN VARIABLE REGION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 61549116212     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Watson L, Wyld P and Catovsky D: Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematology, Jun 30, 2008.
2. Redaelli A, Laskin BL, Stephens JM, Botteman MF and Phases CL: The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 13: 279-287, 2004.
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ and Edwards BK (eds.): Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review 1975-2000. National Cancer Institute, Bethesda, MD, 2003. Available at: http://seer.cancer.gov/csr/1975_2000.
4. Kalil N and Cheson BD: Chronic lymphocytic leukaemia. The Oncologist 4: 352-369, 1999.
5. Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D and Houlston RS: Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br J Haematol 109: 794-799, 2000.
6. Andritsos L and Khoury H: Chronic lymphocytic leukaemia. Current Treat Options Oncology 3: 225-231, 2002.
7. Houlston RS, Catovsky D and Yuille MR: Genetic susceptibility to chronic lymphocytic leukaemia. Leukaemia 16: 1008-1014, 2002.
8. Bizzozero OJ Jr, Johnson KG, Ciocco A, Kawasaki S and Toyoda S: Radiation-related leukaemia in Hiroshima and Nagasaki 1946-1964. Ann Intern Med 55: 522-530, 1967.
9. Arp EW Jr, Wolf PH and Checkoway H: Lymphocytic leukaemia and exposure to benzene and other solvents in the rubber industry. J Occup Med 25: 598-602, 1983.
10. Malone KE, Koepsell TD, Daling JR, Weiss NS, Morris PD, Taylor JW, Swanson GM and Lyon JL: Chronic lymphocytic leukaemia in relation to chemical exposures. Am J Epidemiol 130: 1152-1158, 1989.
11. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH and Catovsky D: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukaemia 8: 1640-1645, 1994.
12. Matutes E and Polliack A: Morphological and immunophenotypic features of chronic lymphocytic leukaemia. Rev Clin Exp Hematol 4: 22-47, 2000.
13. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK and Catovsky D: Improvement of the chronic lymphocytic leukaemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 108: 378-382, 1997.
14. Dighiero G: CLL Biology and prognosis. Hematology (Am Soc Hematol Educ Program): 278-284, 2005.
15. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN and Pasternack BS: Clinical staging of chronic lymphocytic leukaemia. Blood 46: 219-234, 1975.
16. Binet J, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vauqier, Beral HM, Natali JC, Raphael M, Nizet B and Follezou JY: A clinical staging system for chronic lymphocytic leukaemia: prognostic significance. Cancer 40: 855-864, 1977.
17. Binet J, Auquier A, Dighiero G, Chastang C, Piquet H, Goasquin J, Vauqier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S and Gremy F: A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer 48: 198-206, 1981.
18. Chiorazzi N, Rai KR and Ferrarini M: Chronic lymphocytic leukaemia. New Engl J Med 352: 804-815, 2005.
19. Oscier D, Stevens J, Hamblin T, Pickering R and Fitchett M: Prognostic factors in stage AO B-cell chronic lymphocytic leukaemia. Br J Haematol 76: 348-351, 1990.
20. Gallon D: The pathogenesis of chronic lymphocytic leukaemia. Can Med Ass J 94: 1005-1010, 1966.
21. Rozman C, Montserrat E, Feliu E, Granena A, Marin P, Nomdedeu B and Vives Corrons JL: Prognosis of chronic lymphocytic leukaemia: a multivariate survival analysis of 150 cases. Blood 59: 1001-1005, 1982.
22. Melo J, Catovsky D, Gregory W and Gallon D: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 65: 23-29, 1978.
23. Rozman C, Hernandez-Nieto L, Montserrat E and Brugues R: Prognostic significance of bone marrow patterns in chronic lymphocytic leukaemia. Br J Haematol 47: 529-537, 1981.
24. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick HD, Kuhn-Hallek I and Emmerich B: Serum β2 microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukaemia and immunocytoma. Leuk Lymphoma 22: 439-447, 1996.
25. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, Binet JL, Merle-Beral H and Bron D: Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukaemia. Blood 88: 4259-4264, 1996.
26. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E and Emmerich B: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early nonsmoldering chronic lymphocytic leukaemia. Blood 93: 1732-1737, 1999.
27. Damle RN, Wasil T, Fais F, Ghiotto F, Valetta A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M and Chiorazzi N: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood 94: 1840-1847, 1999.
28. Ibrahim S, Keating M, Do K, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM and Albitar M: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukaemia. Blood 98: 181-186, 2001.
29. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M and Kipps TJ: Biology and treatment of chronic lymphocytic leukaemia. Hematology (Am Soc Hematol Educ Program): 153-173, 2003
30. Reed JC: Molecular biology of chronic lymphocytic leukaemia. Semin Oncol 25: 11-18, 1998.
31. Anastasi J, Le Beau MM, Vardiman JW, Fernald AA, Larson RA and Rowley JD: Detection of trisomy 12 in chronic lymphocytic leukaemia by fluorescence in situ hybridization to interphase cell: a simple and sensitive method. Blood 79: 1796-1801, 1992.
32. Stilgenbauer S, Dönner K, Bentz M, Lichter P and Dönner H: Molecular cytogenetic analysis of B-cell chronic lymphocytic leukaemia. Ann Hematol 76: 101-110, 1998.
33. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger, Dohner K, Bentz M and Lichter P: Genomic aberrations and survival in chronic lymphocytic leukaemia. N Engl J Med 343: 1910-1916, 2000.
34. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, Zhang P, Fischer S, Kalachikov SM, Russo J, Edelman I, Efstratiadis A and Dalla-Favera R: Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukaemia. Blood 97: 2098-2104, 2001.
35. Calin GA, Dimitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Adler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F and Croce CM: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukaemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.
36. Lim LP, Lau NC, Garrett-Engele P, Crimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773, 2005.
37. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu C-g, Kipps TJ, Negrini M and Croce CM: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukaemia. New Engl J Med 353: 1793-1802, 2005.
38. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R and Hillmen P, on behalf of the UK National Cancer Research Institute (NCRI) Hematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. The Lancet 370: 230-239, 2007.
39. Kay NE, Rai KR and O'Brien S: Chronic lymphocytic leukaemia: current and emerging treatment approaches. Clin Adv Hematol Oncol 11(Suppl 22): 1-12, 2006.
40. Hamblin T: Chronic lymphocytic leukaemia: one disease or two? Ann Hematol 81: 299-303, 2002.
41. Schroeder HW Jr and Dighiero G: The pathogenesis of chronic lymphocytic leukaemia: analysis of the antibody repertoire. Immunol Today 15: 288-294, 1994.
42. Fais F, Ghiotto F, Hashimoto S, Sellers B, Valetta A, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW Jr, Ferrarini M and Chiorazzi N: Chronic lymphocytic leukaemia B-cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102: 1515-1525, 1998.
43. Oscier DG, Thompsett A, Zhu D and Stevenson FK: Differential rates of somatic hypermutation in VH genes among subsets of chronic lymphocytic leukaemia defined by chromosomal abnormalities. Blood 89: 4153-4160, 1997.
44. Hamblin TJ, Davis Z, Gardiner A, Oscier DG and Stevenson FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood 94: 1848-1854, 1999.
45. Maloum K, Davi F, Merle-Beral H, Pritsch O, Magnac C, Vuillier F, Dighiero G, Troussard X, Mauro FF and Benichou J: Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukaemia. Blood 95: 377-378, 2000.
46. H mutated and unmutated B-CLL tumors show distinct genetic aberration patterns (abstract). Blood 96: 3609a, 2000.
47. H3-21 genes characterize a new subset of chronic lymphocytic leukaemia. Blood 99: 2262-2264, 2002.
48. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, Dohner H and Stilgenbauer S: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukaemia. Blood 100: 1410-1416, 2002.
49. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC and Pettitt AR: Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukaemia. Blood 100: 1404-1409, 2002.
50. Davis ZA, Orchard JA, Corcoran MM and Oscier DG: Divergence from the germline sequence in unmutated chronic lymphocytic leukaemia is due to somatic mutation rather than polymorphisms. Blood 102: 3075, 2003.
51. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO and Staudt LM: Relation of gene expression phenotype to irnmunoglobulin mutation genotype in B-cell chronic lymphocytic leukaemia. J Exp Med 194(11): 1639-47, 2001.
52. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A and Dalla-Favera R: Gene expression profiling of B-cell chronic lymphocytic leukaemia reveals a homogeneous phenotype related to memory B-cells. J Exp Med 194(11): 1625-1638, 2001.
53. Vasconcelos Y, de Vos J, Vallat L, Rème T, Lalanne AI, Wanherdrick K, Michel A, Nguyen-Khac F, Oppezzo P, Magnac C, Maloum K, Ajchenbaum- Cymbalista F, Troussard X, Leporrier M, Klein B, Dighiero G and Davi F: Genes involved in B-cell receptor activation, cytoskeleton organisation and microenvironment interactions are expressed differentially in stable Ig-mutated and progressive Ig-unmutated chronic lymphocytic leukaemia. Leukaemia 19(11): 2002-5, 2005.
54. Hivroz C: Tout ce que vous avez toujours voulu savoir sur la protéine ZAP-70. Médecine/Sciences 21: 150-155, 2005.
55. Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE and Jelinek DF: Chronic lymphocytic leukaemia and normal B-cells. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukaemia 19: 1018-1024, 2005.
56. Cutrona G, Colombo M, Malis S, Reverbi D, Dono M, Tarantino V, Chiorazzi N and Ferrarini M: B lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol 36: 558-569, 2006.
57. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi M, Chilosi M, Caligaris-Cappio F and Ghia P: ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukaemia 20(4): 689-695, 2006.
58. Kurosaki T: Molecular dissection of B-cell antigen receptor signaling. Int J Mol Med 1: 515-527, 1998.
59. Niiro H and Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2: 945-956, 2002.
60. Healy JI and Goodnow CC: Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol 16: 645-670, 1998.
61. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinno LA, Zambello R, Semenzato G and Donella-Deana A: Chronic lymphocytic leukaemia B-cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115(2): 369-377, 2005.
62. Tomlinsom MG, Lin J and Weiss A: Lymphocytes with a complex: adapter proeins in antigen receptor signaling. Immunol Today 21: 584-591, 2002.
63. Steinberg M, Adjali O, Swainson L, Merida P, Di BV, Pelletier L, Taylor N and Noraz N: T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk. Blood 104: 760-767, 2004.
64. Orchard J, Ibbotson R, Best G, Parker A and Oscier D: ZAP-70 in B-cell malignancies. Leuk Lymphoma 46(12): 1689-1698, 2005.
65. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, Lopez-Guillermo A, Campo E and Monserrat E: ZAP-70 expression as a surrogate for immuno-globulin-variable-region mutations in chronic lymphocytic leukaemia. New Engl J Med 348: 1764-1775, 2003.
66. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Steller-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG and Staudt LM: ZAP-70 expression identifies a chronic lymphocytic leukaemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 101: 4944-4951, 2003.
67. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM and Oscier DG: ZAP-10 expression by flow cytometry is a good prognostic marker in CLL and a potential surrogate for immunoglobulin VH gene mutations. Lancet 363: 105-111, 2004.
68. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A and Kipps TJ: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukaemia. New Engl J Med 351: 893-901, 2004.
69. Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R, Holdaway K, Bernal-Hoyos E, Van Der Heiden M, Popma J and Keeney M: An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukaemia. Cytometry. Part B, Clinical Cytometry 70B: 259-269, 2006.
70. Hamblin TJ: Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 20(3): 455-468, 2007.
71. Marti G, Orfao A and Goolsby C: ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue. Cytometry. Part B, Clinical Cytometry 70B: 197-200, 2006.
72. Best OG, Ibbotson RE, Parker AE, Davis ZA, Orchard JA and Oscier DG: ZAP-70 by flow ytometry: a comparison of different antibodies, anticoagulants and methods of analysis. Cytometry. Part B, Clinical Cytometry 70B: 235-241, 2006.
73. Letestu R, Rawstron A, Ghia P, Villamor N, Leuven NB, Boetcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C and Ajchenbaum-Cymbalista F: Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukaemia: a multicentric international harmonization process. Cytometry. Part B, Clinical Cytometry 70B: 309-314, 2006.
74. H mutations. Cytometry. Part B, Clinical Cytometry 70B: 284-292, 2006.
75. Chen Z, Aston E and Yu M: Loss of ZAP-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukaemia. Leukaemia 19: 1503-1505, 2005.
76. Poulain S, Benard C, Daudignon A, Le Baron F, Morel P and Duthilleul P: Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia? Leuk Lymphoma 48(6): 1219-1221, 2007.
77. Sheridan R, Mounajjed T, Ehrmann DE, Hurtubise PE and Schrager JA: Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometry immunophenotyping in patients with chronic lymphocytic leukaemia. Cytometry. Part B, Clinical Cytometry 70B: 320-321, 2006.
78. Boelens J, Phillipe J and Offner F: B-CLL cells from lymph nodes express higher ZAP-70 levels than B-CLL cells from peripheral blood. Leuk Res 31(5): 719-720, 2007.
79. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J and Capra JD: Analysis of somatic mutation in five B-cell subsets of human tonsil. J Exp Med 180: 329-339, 1994.
80. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z and Stevenson FK: Immunoglobulin V genes and CD38 expression in CLL. Blood 95: 2455-2457, 2000.
81. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK and Oscier DG: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukaemia, but CD38 expression may vary during the course of the disease. Blood 99: 1023-1029, 2002.
82. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, Scielzo C and Caligaris-Cappio F: The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukaemia (CLL) patients at risk of disease progression. Blood 101: 1262-1269, 2003.
83. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, Omede P, Scatolini M, Jaksic O, Chiorino G, Efremov D and Malavasi F: CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 110(12): 210-218, 2007.
84. Mead JR, Irvine SA and Ramji DP: Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80: 753-769, 2002.
85. Preiss-Landl K, Zimmermann R, Hammerle G and Zechner R: Lipoprotein lipase: the regulation of tissue-specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 13: 471-481, 2002.
86. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, Kimura EY, Bechet S, Dumas G, Brissard M, Merle-Béral H, Yamamoto M, Dighiero G and Davi F: The LPL/ADAM29 expression ratio is a novel prognostic indicator in chronic lymphocytic leukaemia. Blood 106: 650-657, 2005.
87. Pierce SK: Lipid rafts and B-cell activation. Nat Rev Immunol 2:96-105, 2002.
88. Cerretti DP, DuBose RF, Black RA and Nelson N: Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem Biophys Res Commun 263: 810-815, 1999.
89. Xu R, Cai J, Xu T, Zhou W, Ying B, Deng K, Zhao S and Li C: Molecular cloning and mapping of a novel ADAM gene (ADAM29) to human chromosome 4. Genomics 62: 537-539, 1999.
90. Nückel H, Hüttmann A, Klein-Hitpass L, Schroers R, Führer A, Sellmann L, Dührsen, and Dürig J: Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 47(6): 1053-1061, 2006.
91. Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiß A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Döhner H, Stilgenbauer S, Jäger U and the German CLL Study Group: High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukaemia. Leukaemia 19: 1216-1223, 2005.
92. Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B and Philippe J: Lipoprotein lipase mRNA expression in whole blood is a prognostic marher in B cell chronic lymphocytic leukaemia. Clin Chem 53(2): 204-212, 2007.
93. Stilgenbauer S, Krober A, Busch R, Eichhorst B, Kienle D, Winkler D and Hopfinger G: 17p Deletion predicts for overall survival after fludarabine-based first line therapy in chronic lymhpocytic leukaemia: first analysis of genetics in the CLL4 trial of the GCLLSG. Blood 106: 212a (abstract 715), 2005.
94. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA and Heerema NA: Select high-risk features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukaemia: justification for risk-adapted strategy. J Clin Oncol 24: 437-443, 2006.
95. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M and the German CLL Study Group: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukaemia. Blood 107: 885-891, 2006.
96. Latour S, Chow LM and Veillette A: Differential intrinsic enzymatic activity of Syk and ZAP-70 protein-tyrosine kinases. J Biol Chem 271: 22782-22790, 1996.
97. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A and Kipps TJ: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymophocytic leukaemia. Blood 100: 4609-4614, 2002.
98. Chen L, Apgar J, Huynh L, Dicker F, Ciago-McGahan T, Rassenti L, Weiss A and Kipps TJ: ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukaemia. Blood 105: 2036-2041, 2005.
99. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G and Efremov DG: ZAP-70 enhances B-cell receptor signaling in spite of absent or inefficient tyrosine kinase activation in chronic lymphocytic leukaemia and lymphoma B-cells. Blood 109: 2032-2039, 2007.
100. Futterer K, Wong J, Grucza RA, Chan AC and Waksman G: Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the chrystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 281: 523-537, 1998.
101. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ and Kipps TJ: ZAP-70 is a novel conditional heat-shock protein 90 (Hsp90) client: anhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukaemia. Blood 106: 2506-2512, 2005.
102. Kipps TJ: The B-cell receptor and ZAP-70 in chronic lymphocytic leukaemia. Best Prac Res Clin Haematol 20(3): 415-424, 2007.
103. Damle RN, Ghiotto F, Valette A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P, Vinciguerra VP, Budde P, Frey J, Rai KR, Ferrarini M and Chiorazzi N: B-cell chronic lymphocytic leukaemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99(11): 4087-4093, 2002.
104. Chiorazzi N: Cell proliferation and death: forgotten features of chronic lymphocytic leukaemia. Best Prac Res Clin Haematol 20(3): 399-413, 2007.
105. Damle RN, Batliwalla FM, Ghiotto F, Valetta A, Albesiano E, Sison C, Allen SL, Kolitz J, Vinciguerra VP, Kudalkar P, Wasil T, Rai KR, Ferrarini M, Gregersen PK and Chiorazzi N: Telomere length and telomerase activity delineate distinctive replicative features of the CLL subgroups defined by immunoglobulin V gene mutations. Blood 103(2): 375-382, 2004.
106. Chiorazzi N and Ferrarini M: Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Haematology Am Soc Haematol Educ Program 512: 273-278, 2006.
107. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M and Caligaris-Cappio F: Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukaemia. Blood 97: 2777-2783, 2001.
108. Hellerstein MK: Measurement of T-cell kinetics: recent methodologic advances. Immunology Today 20(10): 438-441, 1999.
109. 2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci USA 99(24): 15345-15350, 2002.
110. Neese RA, Siler SQ, Cesar D, Antelo F, Lee D, Misell L, Patel K, Tehrani S, Shah P and Hellerstein MK: Advances in the stable isotope-mass spectrometric measurement of DNA synthesis and cell proliferation. Anal Biochem 298(2): 189-195, 2001.
111. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Damle RN, Wasil T, Rai KR, Hellerstein MK and Chiorazzi N: In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukaemia B cells. J Clin Invest 115(3): 755-764, 2005.
112. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M, Cosulich E and Ferrarini M: CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukaemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 88(4): 1365-1374, 1996.
113. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L and Hoffbrand AV: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92: 97-103, 1996.
114. Tsukada N, Burger JA, Zwaifler NJ and Kipps TJ: Distinctive features of "nurse-like" cells that differentiate in the context of chronic lymhpocytic leukaemia. Blood 99: 1030-1037, 2002.
115. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U and Malavasi F: CD38 is a signaling molecule in B-cell chronic lymphocytic leukaemia cells. Blood 102: 2146-2155, 2003.
116. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M and Toh CH: In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukaemia cells. Blood 96: 3181-3187, 2000.
117. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF and Kay NE: VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B-cell chronic lymphocytic leukaemia. Blood 104: 788-794, 2004.
118. Burger JA and Kipps TJ: Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymhpocytic leukaemia. Leuk Lymphoma 43: 461-466, 2004.
119. Ghia P and Caligaris-Cappio F: The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 79: 157-173, 2000.
120. Stevenson FK and Caligaris-Cappio F: Chronic lymphocytic leukaemia: revelations from the B-cell receptor. Blood 103: 4389-4395, 2004.
121. Nagasawa T, Kikutani H and Kishimoto T: Molcular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 91: 2305-2309, 1994.
122. Ma Q, Jones D and Springer TA: The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10:463-471, 1999.
123. Burger JA, Burger M and Kipps TJ: Chronic lymphocytic leukaemia B-cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94: 3658-3667, 1999.
124. Mohle R, Failenschmid C, Bautz F and Kanz L: Overexpression of the chemokine receptor CXCR4 in B-cell chronic lymphocytic leukaemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-I). Leukaemia 13: 1954-1959, 1999.
125. 5+ B lymphocytes. Blood 101: 1962-1969, 2003.
126. Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J, Gardiner A, Mould S, Oscier D, Copplestone JA and Prentice AG: ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukaemia (B-CLL). Blood 107: 3584-3592, 2006.